Laparoscopic coeliac axis decompression for Dunbar syndrome: a step-by-step technical note.

Minim Invasive Ther Allied TechnolJul 22, 2026 (epub)
Case ReportGeneral Surgery

Alessia Dessì, Mauro Podda, Raimondo Sanna et al.

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Median arcuate ligament syndrome is a rare cause of chronic postprandial abdominal pain due to extrinsic compression of the coeliac trunk. Surgical decompression remains the mainstay of treatment.

Reported results

Operative time was 90 min. The postoperative course was uneventful. The patient reported complete symptom resolution and tolerated a solid diet from the second postoperative day. She was discharged home on postoperative day four. Two-week CT angiography showed restoration of coeliac trunk calibre, with no residual stenosis or extrinsic compression.

Authors' conclusions

Laparoscopic coeliac axis decompression is a safe and feasible option in patients with Dunbar syndrome. Magnified exposure may facilitate safe dissection and complete release. Clinical follow-up should combine objective vascular imaging with assessment of functional outcomes and quality of life.

Source

PubMed · PMID 42484449

Published in Minim Invasive Ther Allied Technol. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.